DEERFIELD, Ill. — Specialty pharmacy patients now have exclusive access to VIVJOA through AllianceRx Walgreens Pharmacy.

VIVJOA (oteseconazole), manufactured by Mycovia Pharmaceuticals, Inc., is the first FDA-approved medication to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in post-menopausal women or women who are not of reproductive potential.

The addition of this medication brings Walgreens enterprise specialty’s number of exclusive limited distribution drugs to among the highest of specialty pharmacies in the U.S.

“Having Mycovia select us as the exclusive specialty pharmacy partner of VIVJOA is a testament to the thorough care and oversight of this medication provided by Walgreens specialty pharmacists,” says Tracey James, RPh, chief operating officer, Walgreens specialty enterprise. “It’s not only how we care for the patients, but winning exclusive access to a limited distribution drug is also about how we support providers by getting their patients on therapy faster.”

In addition to VIVJOA, the following limited distribution drugs are available at AllianceRx Walgreens Pharmacy and select community-based specialty pharmacies.

Augtyro™ (repotrectinib), manufactured by Bristol Myers Squibb, is an oral prescription medicine used to treat non-small cell lung cancer (NSCLC) in adults that has spread within your chest or to other parts of the body, and is caused by an abnormal ROS1 gene.
Eylea® HD (aflibercept) Injection, manufactured by Regeneron, is approved to treat patients with neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Entyvio® SQ (vedolizumab), manufactured by Takeda, is prescribed as maintenance therapy for adult patients with moderately to severely active ulcerative colitis after induction therapy with ENTYVIO intravenous.
Hemady® (dexamethasone), distributed by Edenbridge Pharmaceuticals, is the first and only 20 mg tablet of dexamethasone indicated for use with other anti-myeloma products for the treatment of adults with multiple myeloma.
For full prescribing information on these drugs, visit their manufacturer’s websites or dailymed.nlm.nih.gov.